These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6423460)

  • 1. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
    Stehman FB; Ehrlich CE; Callangan MF
    Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
    Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
    Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
    Razis DV; Poulakou E; Petounis A; Papadimitriou G; Kosmides P; Delides G
    Oncology; 1982; 39(4):205-8. PubMed ID: 6806735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.
    Rosen GF; Lurain JR; Newton M
    Gynecol Oncol; 1987 Jun; 27(2):173-9. PubMed ID: 3106174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hexamethylmelamine as a single second-line agent in ovarian cancer.
    Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
    Gynecol Oncol; 1990 Jan; 36(1):93-6. PubMed ID: 2104819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
    Greco FA; Johnson DH; Hainsworth JD
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
    Vogl SE; Pagano M; Davis TE; Einhorn N; Tunca JC; Kaplan BH; Arseneau JC
    Cancer Treat Rep; 1982 Jun; 66(6):1285-90. PubMed ID: 6282454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group.
    Wiernik PH; Yeap B; Vogl SE; Kaplan BH; Comis RL; Falkson G; Davis TE; Fazzini E; Cheuvart B; Horton J
    Cancer Invest; 1992; 10(1):1-9. PubMed ID: 1735009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
    Piver MS; Lele S; Barlow JJ
    Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexamethylmelamine and pentamethylmelamine: an update.
    Hahn DA
    Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
    Carlson JA; Day TG; Botts B; Masterson BJ
    Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.
    Lund B; Aabo K; Rørth M; Hansen HH
    Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1089-92. PubMed ID: 6819145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
    Schwartz PE; Lawrence R; Katz M
    Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
    Carmo-Pereira J; Costa FO; Henriques E
    Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
    Coleman M; Pasmantier MW; Silver RT
    Cancer; 1985 May; 55(10):2342-7. PubMed ID: 3921228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.